BofA Securities Downgrades Vir Biotechnology to Neutral, 'Near-term data unlikely to lift sentiment'

  • Investing.com
BofA Securities Downgrades Vir Biotechnology to Neutral, 'Near-term data unlikely to lift sentiment'
(Updated - September 8, 2023 7:45 AM EDT)

BofA Securities analyst lowered forecasts for HBV peak sales and extended potential launch timelines (YE2026e). To be clear, we aren't negative on VIR's technology or the optionality from its pipeline (including the potential for a next-gen COVID-19 antibody) and we believe that its negative enterprise value offers some downside protection. Instead, we acknowledge many near-term trial readouts in HBV (see below) but we don’t think that they are likely to materially change investor sentiment that could drive a re-rating in shares."

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles